Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 18, 2020
Reporting Period: Event date August 18, 2020 (Amendment to Sales Agreement)
Key Financial Metrics
This filing reports on a capital raising mechanism rather than operational financial performance. Specific metrics include:
- Aggregate Offering Price (Revised): $30,000,000 (increased from $10,000,000).
- Shares Sold to Date (as of Aug 10, 2020): 178,601 shares.
- Gross Proceeds to Date (as of Aug 10, 2020): $972,879.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational metrics.
Material Changes Versus Prior Period
The primary material change is the amendment of the At-The-Market (ATM) Sales Agreement with BTIG, LLC:
- Original Agreement (April 16, 2020): Allowed for the sale of common stock up to an aggregate offering price of $10,000,000.
- Amendment No. 1 (August 18, 2020): Increased the aggregate offering price to $30,000,000, inclusive of shares previously sold under the original agreement.
Guidance, Outlook, and Management Commentary
- Capital Raising Strategy: The Company is not obligated to sell any shares under the agreement. Future sales depend on market conditions and capital raising needs.
- Sales Method: Shares may be sold via "at the market offerings" through the Nasdaq Capital Market or other trading markets, subject to placement notices.
- Agent Role: BTIG acts as a sales agent and is not obligated to purchase shares on a principal basis.
- Risks and Contingencies: The filing notes that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful without registration.
Important Facts for Investor Verification
- Verify the current share price and volume to assess the potential dilution impact of the remaining $29,027,121 available under the amended ATM facility.
- Confirm the filing of Amendment No. 1 to the ATM Prospectus Supplement (scheduled for August 19, 2020) to review updated terms.
- Review the full text of Exhibit 1.1 (Amendment No. 1 to At-The-Market Sales Agreement) for specific limitations on sales volume and pricing.
- Monitor subsequent 8-K filings or quarterly reports for actual proceeds generated from this facility, as the $972,879 figure is current only as of August 10, 2020.